Fig. 1From: Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availabilityIdentified challenges related to predictive biomarker assessments in patients with NSCLC, according to participants in the Virtual Meeting. Answers were provided by 9 participants via a multiple-choice question. * Specific determination of exon 19 and exon 21 mutations onlyBack to article page